LIFECORE BIOMEDICAL, INC. Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1
LIFECORE BIOMEDICAL, INC. (LFCR) reported Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 of $0 for the 3-month period ending 2024-11-24, per its 10-Q filed 2025-01-02.
Financial Statements › Shareholders' Equity
us-gaap:PreferredStockConvertibleDownRoundFeatureIncreaseDecreaseInEquityAmount1 · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. preferred stock convertible down round feature increase decrease in equity amount1 for the quarter ending 2024-11-24 was $0.00.
| Period end | Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 | Preferred Stock Convertible Down Round Feature Increase Decrease In Equity Amount1 3 month |
|---|---|---|
| 2024-11-24 | $0.00 10-Q · filed 2025-01-02 | |
| 2024-10-03 | -$2.13M 10-KT · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |